Welcome to our dedicated page for Tourmaline Bio news (Ticker: TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Tourmaline Bio, Inc. (TRML) generated a steady flow of news as a late-stage clinical biotechnology company focused on immune and inflammatory diseases, particularly cardiovascular inflammation and thyroid eye disease. Company press releases emphasize its lead asset, pacibekitug (TOUR006), a long-acting, fully human, anti-IL-6 monoclonal antibody being evaluated across multiple indications.
News items for TRML prominently feature updates on the Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease. These include announcements of over-enrollment, timing of topline data, and detailed topline and follow-up results describing rapid, deep, and durable hs-CRP reductions and pharmacodynamic effects on biomarkers such as lipoprotein(a), fibrinogen, and serum amyloid A. Additional releases cover plans for a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease (ASCVD) and a Phase 2 proof-of-concept trial in abdominal aortic aneurysm (AAA).
Tourmaline’s news flow also covers its Phase 2b spiriTED trial in thyroid eye disease, scientific publications and conference presentations related to IL-6 signaling and cardiovascular and ophthalmic disease, and corporate events such as participation in investor conferences and the strengthening of its Cardiovascular Scientific Advisory Board.
A major development in the TRML news stream is the announcement of an Agreement and Plan of Merger with Novartis AG, under which a Novartis subsidiary launched a cash tender offer to acquire all outstanding Tourmaline shares. Subsequent communications and SEC filings report the completion of the tender offer, the closing of the merger, and the resulting change in control and delisting of TRML from the Nasdaq Global Select Market.
Investors and observers using this news page can review historical press releases and related disclosures to understand Tourmaline’s clinical progress with pacibekitug, its scientific positioning around IL-6–driven inflammation, and the sequence of events that led to its acquisition by Novartis and transition from a public to a privately held subsidiary.
Tourmaline Bio (NASDAQ: TRML) has entered into a definitive merger agreement with Novartis AG in a deal valued at approximately $1.4 billion. Under the agreement, Novartis will acquire Tourmaline for $48.00 per share in cash, representing a 59% premium to Tourmaline's last closing price and a 127% premium to its 60-day volume-weighted average.
The acquisition centers on Tourmaline's lead asset pacibekitug, a long-acting anti-IL-6 monoclonal antibody with potential best-in-class properties for treating cardiovascular diseases. The transaction, unanimously approved by both companies' boards, is expected to close in Q4 2025, subject to customary conditions including regulatory approvals and tender of majority shares.
Tourmaline Bio (NASDAQ: TRML) presented additional data from its Phase 2 TRANQUILITY trial of pacibekitug at the ESC Congress 2025. The trial demonstrated significant results in treating patients with elevated hs-CRP and chronic kidney disease.
The data showed consistent reductions in high-sensitivity C-reactive protein (hs-CRP) across various patient subgroups. Notably, pacibekitug achieved >85% hs-CRP reductions in the 50mg quarterly dosing arm, becoming the first IL-6 inhibitor to demonstrate such efficacy with quarterly dosing. The drug also showed statistically significant reductions in secondary biomarkers including lipoprotein(a), fibrinogen, and serum amyloid A.
Based on these positive results, Tourmaline plans to initiate a Phase 2 proof-of-concept study in abdominal aortic aneurysm (AAA) and continue preparations for a Phase 3 cardiovascular outcomes trial in ASCVD patients.
Tourmaline Bio (NASDAQ: TRML) reported Q2 2025 financial results and highlighted significant progress in its clinical programs. The company announced positive topline results from the Phase 2 TRANQUILITY trial of pacibekitug, demonstrating rapid and significant reductions in high-sensitivity C-reactive protein with quarterly dosing.
Key financial metrics include cash position of $256.4 million as of June 30, 2025, providing runway into H2 2027. Q2 2025 saw net loss of $23.1 million ($0.90 per share), with R&D expenses at $19.6 million and G&A expenses at $6.3 million.
The company plans to initiate a Phase 2 proof-of-concept trial in abdominal aortic aneurysm in H2 2025 and is preparing for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease. Additional TRANQUILITY trial data will be presented at the upcoming European Society of Cardiology Congress.
Tourmaline Bio (NASDAQ: TRML) has reported its Q4 and full year 2024 financial results. The company has successfully over-enrolled its Phase 2 TRANQUILITY trial to 143 participants, with topline data expected in Q2 2025. The trial evaluates pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.
Financial highlights include a strong cash position of $294.9 million as of December 31, 2024, providing runway into H2 2027. R&D expenses increased to $67.0 million for FY2024, up from $32.4 million in 2023. Net loss widened to $73.2 million for FY2024 compared to $42.1 million in 2023.
The company strengthened its Cardiovascular Scientific Advisory Board with the appointments of several distinguished experts and continues to advance its clinical programs in cardiovascular inflammation and thyroid eye disease, with the Phase 2b spiriTED trial results expected in H2 2025.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025.
The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 4:20 pm ET in Miami. Interested parties can access both the live webcast and replay through the 'Events and Presentations' section under News & Investors on Tourmaline Bio's website at ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York.
The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will participate in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:30 pm ET. Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section on Tourmaline Bio's investor relations website at ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML) has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board. Dr. Ridker, who serves as Eugene Braunwald Professor of Medicine at Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, brings over 30 years of expertise in cardiovascular disease research.
Dr. Ridker's contributions include developing the first FDA-approved diagnostic test for vascular inflammation (hs-CRP), demonstrating statin therapy's dual lipid-lowering and anti-inflammatory effects, and proving the inflammation hypothesis of atherothrombosis in humans. His work has led to the development of various anti-inflammatory agents targeting heart disease.
This appointment comes as Tourmaline awaits results from its Phase 2 TRANQUILITY trial and prepares for the future development of pacibekitug to reduce inflammation in cardiovascular diseases.
FAQ
What is the current stock price of Tourmaline Bio (TRML)?
What is the market cap of Tourmaline Bio (TRML)?
